Enzalutamide-resistant LNCaP ARF877L Mutation KI model
We have established an enzalutamide-resistant (LNCaP AR-F877L mutation) KI prostate cancer model to support the development of next-generation therapeutics. An LNCaP AR-F877L KI cell line was shown to be resistant to enzalutamide, and in vivo animal validation studies demonstrated that enzalutamide was not efficacious to prevent tumor growth using this drug-resistant model.
Check out our comprehensive platform of drug-resistant animal models
Enzalutamide-resistant LNCAP AR F877L mutant KI model
Related Content
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a key mediator of non-canonical Wnt signaling and plays a critical role...
VIEW RESOURCENatural killer (NK) cells play a crucial role in the immune system and can recognize and kill cancer cells. Research...
VIEW RESOURCE